Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 14/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103017 | 0.90 | HSD11B1 (0.67) | HSD11B1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3101403 | 0.90 | HSD11B1 (0.61) | HSD11B1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3090546 | 0.89 | HSD11B1 (0.65) | HSD11B1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3110797 | 0.86 | HSD11B1 (0.70) | HSD11B1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3113859 | 0.84 | HSD11B1 (0.64) | HSD11B1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3109651 | 0.83 | HSD11B1 (0.60) | HSD11B1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3100530 | 0.83 | AVPR1A (0.58) | HSD11B1CHRM1AVPR1A | |
| SCHEMBL3102309 | 0.82 | HSD11B1 (0.68) | HSD11B1CHRM1CHRM2CHRM4CHRM5 | |
| SCHEMBL3107980 | 0.82 | FPR2 (0.59) | HSD11B1CHRM1 | |
| SCHEMBL3103117 | 0.81 | HSD11B1 (0.63) | HSD11B1CHRM1CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071622-B2 | 1-[1-(6-Methoxy-1H-indole-2-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | claimed |
| US-20080139548-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | claimed |
| US-8071622-B2 | 1-[1-(6-Methoxy-1H-indole-2-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071622-B2 | 1-[1-(6-Methoxy-1H-indole-2-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071622-B2 | 1-[1-(6-Methoxy-1H-indole-2-carbonyl)-piperidin-4-yl]-1,3-dihydro-benzoimidazol-2-one; vasopressin receptors antagonist; antidepressant, anxiolytic agent; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMAN-LA ROCHE INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-7799923-B2 | Vasopressin receptor antagonists; (4-Benzotriazol-1-yl-piperidin-1-yl)-(5-chloro-1H-indol-2-yl)-methanone; antidepressants, anxiolytic agents; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799923-B2 | Vasopressin receptor antagonists; (4-Benzotriazol-1-yl-piperidin-1-yl)-(5-chloro-1H-indol-2-yl)-methanone; antidepressants, anxiolytic agents; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799923-B2 | Vasopressin receptor antagonists; (4-Benzotriazol-1-yl-piperidin-1-yl)-(5-chloro-1H-indol-2-yl)-methanone; antidepressants, anxiolytic agents; dysmenorrhea, hypertension, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder | HOFFMANN-LA ROCHE INC. (US) | 2010-09-21 | — | — | US | disclosed |
| EP-2089381-B1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-06-30 | — | — | EP | disclosed |
| EP-2089381-A1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-08-19 | — | — | EP | disclosed |
| US-20080269290-A1 | Indoles | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20080139618-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139618-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139618-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008068184-A1 | INDOLES WHICH ACT AS VIA RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | WO | disclosed |
| US-20080139548-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139548-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139548-A1 | INDOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-12 | — | — | US | disclosed |
| US-20080139617-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139617-A1 | INDOLES | HOFFMAN-LA ROCHE INC. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139548-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | HSD11B1 1172/4885CHRM1 54/4885CHRM2 169/4885 |
| US-20080139617-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | HSD11B1 1172/4885CHRM1 54/4885CHRM2 169/4885 |
| US-20080269290-A1 | Indoles | HTR1A, AVPR1A, TPH1 | HSD11B1 1172/4885CHRM1 54/4885CHRM2 169/4885 |
| US-20080139618-A1 | INDOLES | HTR1A, AVPR1A, TPH1 | HSD11B1 1172/4885CHRM1 54/4885CHRM2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.